At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SPRY ARS PHARMACEUTICALS INC
Market Closed 09-27 16:00:00 EDT
14.33
-0.18
-1.24%
盘后14.32
-0.01-0.07%
18:45 EDT
High14.99
Low13.83
Vol615.99K
Open14.55
D1 Closing14.51
Amplitude7.99%
Mkt Cap1.39B
Tradable Cap641.23M
Total Shares96.94M
T/O8.77M
T/O Rate1.38%
Tradable Shares44.75M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
ARS Pharmaceuticals Launches Neffy Nasal Spray in US
ARS Pharmaceuticals Announces U.S. Availability of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
BRIEF-Ars Pharmaceuticals Submits SNDA To FDA For Neffy® 1 Mg Dose For Pediatric Patients With Type I Allergic Reactions Who Weigh 15 To 30 KG (33-66 Lbs.)
ARS Pharmaceuticals Launches Pre-Ordering Services for Neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.